United Therapeutics Corporation UTHR
Set alert
At close · Oct 30
After hours · Oct 30, 6:34 PM ET
- YTD
- +22.88%
- 1 year
- +32.01%
- Open
- 600.00
- Prev close
- 593.54
- Mkt cap
- 25.68B
- Vol
- 518.24K
- Avg vol
- 716.02K
- EPS
- 27.92
- P/E
- 21.44
- Div yield
- 0.00%
More statistics
- Low
- 593.57
- High
- 609.99
- Forward P/E
- 17.67
- Beta
- 0.49
- Short ratio
- 2.42
- Inst. own
- 100.39%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 525.55
- 200-d avg
- 530.92
- 1y target
- 670.93
5D chart
Events in this range
- Oct 28, 2026Rating: JP Morgan · Overweight → Overweight
Signals (150)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:25 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:40 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 1:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 1:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:45 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 11:55 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:50 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:15 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 11:00 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:35 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:05 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:55 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:30 AM | 2 days ago |
| RSI: Overbought | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 3:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:50 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:15 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:50 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 11:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:25 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:20 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:50 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 5 days ago |
| RSI: Overbought | Oct 27, 3:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:05 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:25 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:15 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:45 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| RSI: Overbought | Oct 26, 3:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:20 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:05 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:15 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:20 AM | 6 days ago |
News
2 days ago zacks.com
SGIOY vs. UTHR: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and United Therapeutics (UTHR).
-
4 days ago benzinga.com
JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $695
JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and lowers the price target from $710 to $695.
4 days ago zacks.com
Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 days ago benzinga.com
$100 Invested In United Therapeutics 15 Years Ago Would Be Worth This Much Today
United Therapeutics (NASDAQ:UTHR) has outperformed the market over the past 15 years by 6.41% on an annualized basis producing an average annual return of 19.23%. Currently, United Therapeutics has a…
4 days ago businesswire.com
United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug…
6 days ago defenseworld.net
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company Stock
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Friday, October 23rd. The shares were sold at an average…
-
1 week ago benzinga.com
RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $697
RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $708 to $697.
1 week ago businesswire.com
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
SILVER SPRING, M.D. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of…
1 week ago businesswire.com
United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2026 financial results in a…
-
1 week ago benzinga.com
United Therapeutics Opens Third Designated Pathogen-Free Facility, The Dr. Bartley P. Griffith And Dr. Robert A. Montgomery Xenograft Production Facility, In Houston, Texas
Named for Dr. Bartley P. Griffith and Dr. Robert A. Montgomery, pioneers in xenotransplantation, the biosecure facility is purpose-built to manufacture United Therapeutics’ xenokidneys and xenohearts…
1 week ago businesswire.com
United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated…
1 week ago defenseworld.net
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company Stock
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction on Friday, October 16th. The shares were sold at an…
1 week ago benzinga.com
Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years
United Therapeutics (NASDAQ:UTHR) has outperformed the market over the past 5 years by 11.98% on an annualized basis producing an average annual return of 23.16%. Currently, United Therapeutics has a…
-
1 week ago benzinga.com
Leerink Partners Maintains Outperform on United Therapeutics, Raises Price Target to $725
Leerink Partners analyst Roanna Ruiz maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $685 to $725.
-
1 week ago benzinga.com
The FDA Clears United Therapeutics' Investigational New Drug Application To Proceed With SUMMIT Trial Of Treprostinil Soft Mist Inhaler In Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company’s…
1 week ago businesswire.com
United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug…
2 weeks ago defenseworld.net
United Therapeutics (NASDAQ:UTHR) CEO Sells $5,129,905.00 in Stock
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company's stock in a transaction dated Wednesday, October 14th. The shares were sold at…
2 weeks ago defenseworld.net
United Therapeutics (NASDAQ:UTHR) Stock: Insider Paul Mahon Sells 8,300 Shares
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the business's stock in a transaction that occurred on Thursday, October 15th. The stock was sold…
2 weeks ago defenseworld.net
2,241 United Therapeutics Corporation $UTHR Shares Sold by First Citizens Bank & Trust Co.
First Citizens Bank and Trust Co. trimmed its position in shares of United Therapeutics Corporation (NASDAQ: UTHR) by 59.6% in the undefined quarter, according to the company in its most recent Form…
2 weeks ago zacks.com
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.
2 weeks ago proactiveinvestors.com
Liquidia shares surge 25% as settlement ends United Therapeutics litigation
Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of…
2 weeks ago zacks.com
SGIOY or UTHR: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and United Therapeutics (UTHR).
2 weeks ago 247wallst.com
United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%
A patent court ruling wiped out nearly half of Liquidia's stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank.
2 weeks ago zacks.com
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
2 weeks ago barrons.com
This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario.
Liquidia surges after reaching a $380.7 million settlement with United Therapeutics resolving patent disputes for its lung disease drug.
2 weeks ago benzinga.com
Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain Even as September Inflation Report Comes In Hotter Than Expected— ASML, AZZ, GME in Focus (UPDATED)
U.S. stock futures were higher on Wednesday, as the Dow Jones, S&P 500 and Nasdaq 100 indices rose, following Tuesday's lower close.
2 weeks ago benzinga.com
Liquidia Settles Bitter Fight With United Therapeutics
Liquidia (LQDA) stock jumped 40% after settling all lawsuit battles with United Therapeutics for $380.7M. YUTREPIA PAH sales continue.
2 weeks ago benzinga.com
Why Enovix Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Enovix jumps 6.8% after securing a 100,000-unit battery order from a multinational drone maker, with deliveries planned for H1 2027.
2 weeks ago benzinga.com
Liquidia Corporation Stock Is Trending In After-Hours Following United Therapeutics Settlement: What You Should Know
Liquidia shares surged 42.48% in after-hours trading after settling all pending litigation with United Therapeutics over YUTREPIA patents.
-
2 weeks ago benzinga.com
Liquidia Will Continue To Advance YUTREPIA And L606 Clinical Programs As Previously Outlined; Liquidia Has Submitted A Supplement To Remove The PH-ILD Indication From YUTREPIA’ ’s Label And No Longer Promotes It For PH-ILD
The settlement follows the September 30, 2026, ruling by the U.S. District Court for the District of Delaware (the Court) that claims 1 and 14 of U.S. Patent No. 11,826,327 (the ’327 patent) are…
-
2 weeks ago benzinga.com
Liquidia Enters Into A Global Settlement Agreement With United Therapeutics That Resolves All Pending Litigation Between The Companies; Settlement Fully Resolves Six Ongoing Lawsuits Between Liquidia And United Therapeutics; Liquidia To Pay Net $380.70M In Installments In 2026 And 2027; Liquidia Will Make A Net Payment To UTHR Of $175M Within 30 Business Days
Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced…
2 weeks ago businesswire.com
United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that two oral and five poster…
-
3 weeks ago benzinga.com
RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $708
RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $677 to $708.
-
3 weeks ago benzinga.com
Morgan Stanley Maintains Equal-Weight on United Therapeutics, Raises Price Target to $566
Morgan Stanley analyst Terence Flynn maintains United Therapeutics (NASDAQ:UTHR) with a Equal-Weight and raises the price target from $515 to $566.
1 month ago benzinga.com
This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Analysts upgraded BJRI, UTHR, OXY, BP and REGN, raising ratings and/or price targets.
-
1 month ago benzinga.com
United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia
Shares of United Therapeutics are rising Thursday following a federal court victory in its patent litigation against competitor Liquidia.
1 month ago benzinga.com
Progress Software, Nft And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures were mixed as Progress Software fell after results; Corteva, NFT, Vivakor and other stocks also dropped in premarket trading.
-
1 month ago benzinga.com
BTIG Upgrades United Therapeutics to Buy, Announces $728 Price Target
BTIG analyst Julian Harrison upgrades United Therapeutics (NASDAQ:UTHR) from Neutral to Buy and announces $728 price target.
-
1 month ago benzinga.com
Reported Earlier, United Therapeutics Prevails In Delaware Court Ruling Finding Liquidia Infringes Two Claims Of Patent On Inhaled Treprostinil For PH-ILD Via Yutrepia Marketing
As a result of the Court’s decision, United Therapeutics believes that it is entitled to an order instructing the U.S. Food and Drug Administration (FDA) to withdraw approval of Liquidia’s new drug…
1 month ago benzinga.com
Why is Liquidia (LQDA) Stock Trending After Hours?
Liquidia Corp. shares gained 0.13% after hours after closing 57.19% lower following an adverse patent ruling.
1 month ago benzinga.com
Nasdaq 100 Climbs as Cooler PCE Cuts Rate Hike Bets, Micron Earnings Loom: Stock Market Today
Nasdaq 100 gains as softer PCE inflation cools Fed rate-hike bets, with oil above $91 and Micron earnings due after the bell Wednesday.
1 month ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
1 month ago benzinga.com
Goldman Sachs Initiates Coverage On United Therapeutics with Sell Rating, Announces Price Target of $321
Goldman Sachs analyst Andrea Newkirk initiates coverage on United Therapeutics (NASDAQ:UTHR) with a Sell rating and announces Price Target of $321.
1 month ago benzinga.com
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In Q3
Healthcare stocks UTHR, COLL and AHG show oversold RSI levels near or below 30, potentially offering undervalued buying opportunities.
-
2 months ago benzinga.com
United Therapeutics Says FDA Accepts sNDA For Nebulized Tyvaso Inhalation Solution To Treat IPF
Nebulized Tyvaso® (treprostinil) Inhalation Solution will be the first and only inhaled anti-fibrotic treatment for idiopathic pulmonary fibrosis (IPF) if approved by the U.S. Food and Drug…
-
2 months ago benzinga.com
United Therapeutics To Present Eight Clinical Studies In PAH And Fibrotic Lung Diseases At ESC 2026 In Munich And ERS 2026 In Barcelona
ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening…
-
2 months ago benzinga.com
United Therapeutics Announces Full Enrollment Of TETON-PPF Study Evaluating Use Of Tyvaso Inhalation Solution For Treatment Of Progressive Pulmonary Fibrosis; Topline Data Expected In H2 Of 2027
Approximately 200,000 patients in the United States have PPF, with limited treatment optionsTopline data expected in the second half of 2027United Therapeutics Corporation (Nasdaq: UTHR) announced…
-
2 months ago benzinga.com
RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $677
RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $704 to $677.
-
3 months ago benzinga.com
United Therapeutics Announces Publication of ADVANCE OUTCOMES Study in The Lancet; Ralinepag Remains Investigational for PAH
The long-term, pivotal, phase 3 ADVANCE OUTCOMES study of ralinepag in predominantly pre-treated patients with pulmonary arterial hypertension (PAH) met its primary endpoint and important secondary…
-
3 months ago benzinga.com
JP Morgan Maintains Overweight on United Therapeutics, Raises Price Target to $687
JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and raises the price target from $685 to $687.